Your GLP-1 Clinic Might Be in Legal Trouble — How to Tell If Yours Is Compliant Thousands of patients are injecting compounded weight-loss drugs from clinics operating in a legal gray zone — and the FDA is cracking down.

The GLP-1 Reckoning Has Arrived

It started quietly: a compliance guideline update, an FDA announcement about "decisive enforcement," and a single press release in February 2026 that changed everything. The FDA declared that semaglutide and tirzepatide are no longer in shortage — which means compounding pharmacies can no longer legally manufacture these drugs in the easy, mass-market way they've been doing for the last 18 months. By March 2026, the enforcement followed: 30 warning letters issued, clinic shutdowns initiated, and federal referrals sent to the Department of Justice.

The problem is that thousands of patients are still getting weekly injections from clinics that may not have adapted. Some clinics are quietly continuing to dispense compounded semaglutide and tirzepatide as if nothing changed. Others are operating under outdated legal interpretations. And many patients have no way of knowing which category their provider falls into.

If you're on a GLP-1 weight-loss program right now, there's a real chance your clinic is skirting the line — or has already crossed it. This article walks you through what changed, what's legal now, and how to spot a clinic that's still playing by 2024 rules.

What Changed: The FDA Shortage List Was Your Cover

For the first time in GLP-1 history, there was a genuine national shortage of semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro). Patients couldn't get brand-name prescriptions filled. In response, the FDA issued a formal shortage exemption that allowed 503B outsourcing facilities and compounding pharmacies to legally manufacture and distribute these drugs without FDA approval — a special carve-out that existed only because supply couldn't meet demand.

That exemption made compounded GLP-1s legal, accessible, and cheap. Clinics across Florida, Texas, Arizona, and Georgia pivoted overnight: instead of requiring patients to jump through hoops to get brand-name prescriptions, they could offer compounded semaglutide for $200–300 per month instead of $900+. Patients flocked to these clinics. Telehealth platforms like Hims & Hers advertised compounded GLP-1s as equivalent to brand-name alternatives. The market exploded.

Then, in late 2025 and early 2026, supply stabilized. Novo Nordisk increased manufacturing capacity. Eli Lilly ramped up Zepbound production. The shortage was declared officially over. And when that happened, the legal exemption expired.

According to the FDA announcement in February 2026^[1], compounding these drugs without an active shortage declaration is now illegal. The FDA stated its intent to use "all available compliance and enforcement tools" against companies continuing to manufacture and market compounded semaglutide and tirzepatide.

The enforcement wasn't theoretical. Within weeks, the FDA issued warning letters to 30 telehealth companies^[2] for misleading claims about compounded GLP-1s. Hims & Hers, one of the largest telehealth providers offering compounded semaglutide, announced it would stop offering compounded formulations^[3] and pivot to brand-name Novo Nordisk products instead.

The Legal Gray Zone: What's Still Allowed (and What Isn't)

This is where it gets complicated. The FDA didn't say all compounding is illegal — it said unlicensed, mass-market compounding of drugs no longer in shortage is illegal.

A few narrow exceptions remain:

Licensed 503A and 503B pharmacies can still compound semaglutide or tirzepatide if: - A licensed physician prescribes it for a documented clinical reason that cannot be met by a brand-name product (e.g., a patient has an allergy to an inactive ingredient, or requires a non-standard dose) - The compounding is done on a per-patient basis, not mass-manufactured for inventory - The prescription explicitly documents the clinical difference or necessity

Licensed physicians can compound these drugs in-office if: - The physician performs the compounding themselves (or immediately supervises a technician onsite — no remote supervision allowed) - The compounding is done for individual patient needs, not stockpiled - Proper pharmaceutical-grade ingredients are sourced from FDA-registered distributors

What's illegal now: - Operating a 503B facility that mass-manufactures compounded semaglutide or tirzepatide without a documented shortage - A clinic offering "compounded semaglutide injections" without citing a specific clinical reason tied to an individual patient's needs - Marketing compounded GLP-1s as equivalent to or a substitute for brand-name products - Sourcing active pharmaceutical ingredients from "research-only" suppliers or unlicensed distributors - Offering compounded GLP-1s remotely without real physician oversight

Red Flags: Signs Your Clinic Might Not Be Compliant

The clinic offers compounded semaglutide but won't name the compounding pharmacy. If a clinic is proud of its sourcing, it will tell you the name of the licensed pharmacy or facility preparing your injections and be transparent about whether it's a 503A or 503B facility. Vagueness here is a major warning sign.

Pricing seems too good to be true ($200–300/month for semaglutide). Brand-name Ozempic and Wegovy now cost $499–650 per month through direct-pay programs (down from $900+ in 2025). If a clinic is offering compounded versions for significantly less, ask why. The price gap used to signal savings; now it may signal grey-market sourcing or unlicensed compounding.

The clinic markets compounded GLP-1s as "equivalent to Ozempic" or "the same as Wegovy." This is one of the specific claims the FDA cited in its warning letters. The FDA does not consider compounded drugs equivalent to brand-name drugs because they haven't undergone FDA safety and efficacy review. Any clinic making this claim is directly violating FDA guidance.

No clear physician oversight or medical documentation. Compliant clinics require an initial consultation with a licensed physician (not a nurse practitioner consulting remotely), baseline lab work, regular follow-ups, and clear documentation of medical necessity. If you've never spoken to a physician or had lab work done, that's a red flag.

No mention of a licensed pharmacy supplier or "503B facility." A compliant clinic will disclose whether its compounded products come from a licensed 503B outsourcing facility. Transparency about the supply chain is a hallmark of legal operations.

Aggressive recruitment or marketing pressure. Clinics that are quietly uncertain about their legal status often ramp up marketing and patient acquisition to maximize revenue before enforcement arrives. High-pressure sales tactics are a behavioral signal that something may be off.

Green Flags: What Compliant Clinics Look Like

Licensed, in-person physician involvement. The clinic is run by or partners with a licensed MD or DO who conducts initial consultations, reviews lab work, and signs off on all prescriptions. This is not delegated to nurse practitioners or remote consultants.

Clear documentation of the pharmacy source. The clinic discloses the name of the licensed compounding pharmacy or 503B facility preparing your medication. It can answer questions about the source of active pharmaceutical ingredients and the compounding protocols used.

Detailed informed consent and disclosure. You receive clear paperwork explaining that your medication is compounded (not FDA-approved), the potential risks, and the clinic's rationale for recommending compounded versus brand-name options. Compliant clinics are transparent, not evasive.

Lab work and ongoing monitoring. You're required to provide baseline labs (liver function, kidney function, glucose, etc.) before starting, and you have regularly scheduled follow-ups — not just a one-time consultation.

Reasonable pricing aligned with market rates. If the clinic offers brand-name Ozempic or Wegovy through programs like Novo Nordisk's $499/month direct-pay or Eli Lilly's Lilly Direct ($349–499), you're seeing competitive but not suspiciously low pricing.

Clear naming of products and formulations. The clinic tells you exactly what you're receiving: "Ozempic 0.5 mg pen," "Wegovy injection," or "Compounded semaglutide from [Pharmacy Name] 503B facility." No proprietary rebranding or vague product names.

How GlowRoute Helps You Find Compliant Clinics

The GlowRoute clinic finder filters for GLP-1 programs that meet strict compliance criteria: licensed physicians, transparent pharmacy sourcing, documented medical necessity, and adherence to current FDA guidance. When you search for "GLP-1 clinic near me" or "weight loss clinic Florida," you're seeing providers that have been vetted for physician supervision, legitimate sourcing, and legal operating status.

This matters because the clinic landscape is fragmenting. As enforcement accelerates in 2026, patients will increasingly have two choices: well-established telemedicine platforms pivoting to brand-name drugs (like Hims & Hers moving to Novo Nordisk products), or small local clinics offering gray-market compounded versions at rock-bottom prices. The legal risk and quality risk fall entirely on the patient.

GlowRoute's clinic filter removes that guesswork. Instead of betting on whether your clinic's legal interpretation will survive an FDA audit, you can find programs backed by licensed physicians and transparent supply chains. The pricing may be higher than the cheapest compounded alternatives — but you're also not risking dosing errors, unregulated ingredients, or clinic shutdown.

What This Means for You

If you're currently on compounded semaglutide or tirzepatide: Ask your clinic three direct questions: (1) What is the name of the licensed compounding pharmacy or 503B facility supplying your medication? (2) Has my physician documented a specific clinical reason for compounding instead of recommending brand-name alternatives? (3) What happens if the clinic stops offering this product due to regulatory pressure? If you get evasive answers, it's time to switch providers.

If you're looking to start GLP-1 treatment: Prioritize licensed clinics with transparent physician oversight and clear sourcing. The cost difference between compliant clinics and gray-market providers is real — but so is the risk. Unregulated compounded medications have led to adverse events including overdosing, severe gastrointestinal complications, and hospitalizations.

If your clinic is offering both brand-name and compounded options: Ask why they're still dispensing compounded versions, and under what specific legal exemption. If the answer isn't clear and documented, that's a warning sign. Compliant clinics are increasingly moving exclusively to brand-name products because the legal and liability risks of compounding have become untenable.

Document your decision and your informed consent. If you choose to stay with a compounded GLP-1 provider, make sure you have written documentation of your informed consent and the clinic's stated rationale. This protects you in case enforcement creates disruption.

---

Ready to find a licensed, medically supervised GLP-1 program in your area? Search GlowRoute's curated clinic directory to compare compliant weight-loss providers near you. Filter by location, physician credentials, and program type — and connect with programs operating at the highest legal and safety standards.

→ Find a compliant GLP-1 clinic near you on GlowRoute^[4]